Literature DB >> 7142926

Stool occult blood screening for colorectal cancer.

P S Frame, B A Kowulich.   

Abstract

During a five-year prospective study of patient compliance with the Hemoccult slide test as a screen for colorectal cancer, 772 adults above 40 years of age received 1,693 sets of Hemoccult slides. Overall compliance with returning the slides was 75 percent. Compliance remained high with repeat testing. Sixty percent of patients returned all sets of slides. Thirty percent of patients who did not return the first two sets of slide ultimately changed their behavior and returned subsequent slides. Two to five minutes of provider time were required for instruction and distribution of the first set of slides. Distribution of subsequent sets of slides required less than one minute of provider time. Three cancers were detected during the study period. Two of these cancers were diagnosed only by colonoscopy or subsequent surgery and were missed by rigid sigmoidoscopy and barium enema. Stool occult blood screening for colorectal cancer is accepted by patients and requires little physician time in the private practice, fee-for-service setting.

Entities:  

Mesh:

Year:  1982        PMID: 7142926

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  4 in total

1.  Occult blood testing for early detection of colorectal cancer: diagnostic outcomes.

Authors:  T G Hislop; B J Morrison; P E Hoogewerf; S D Burns; R Sizto
Journal:  Can Fam Physician       Date:  1987-12       Impact factor: 3.275

Review 2.  The pros and cons of fecal occult blood testing for colorectal neoplasms.

Authors:  J B Simon
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Hemoccult II Screening for Bowel Cancer: Will Family Practice Patients Accept It?

Authors:  J F Sangster; T M Gerace; M J Bass
Journal:  Can Fam Physician       Date:  1986-02       Impact factor: 3.275

4.  Patient compliance with screening for fecal occult blood in family practice.

Authors:  P E Hoogewerf; T G Hislop; B J Morrison; S D Burns; R Sizto
Journal:  CMAJ       Date:  1987-08-01       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.